TF and Sepsis: In sepsis (e.g., COVID-19), if the patient with “silent” vEA-VMTD with “microthrombi strings” composed of platelet-ULVWF multimer complexes undergoes a vascular access (e.g., surgery, vascular procedure/device, or mechanical ventilation in ICU) triggering vascular damage, it would release of TF from SET/EVT of damaged venous vasculature and activate the TF-FVIIa complex-induced coagulation cascade (i.e., fibrinogenesis), which produces numerous “fibrin meshes”.